Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
The purpose of this study is to characterize the time course of B cell activation after
 allergen challenge, and more specifically measure the M1 prime related biomarkers.
M1 prime is a segment of IgE found only in the membrane form of IgE and not on soluble IgE
 found in serum. Membrane IgE (and M1prime) is expressed on IgE-switched B cells, IgE-memory B
 cels, and IgE-plasmablasts. Depletion of IgE-switched B cells and plasmablasts will reduce
 IgE-producing cells and serum IgE, and may be a target for treatment of allergic asthma. A
 humanized antibody targeting M1 prime is being developed by Genentech, Inc., as a potential
 therapeutic for asthma.

 Currently, the efficacy of MEMP1972A is being assessed in an allergen challenge study in mild
 asthmatics (MOP4843g). Extensive biomarker samples have been incorporated in that study to
 characterize the mechanism of action (MOA) as well as the kinetics of the MOA of MEMP1972A,
 which are poorly understood at this time. Furthermore, samples for the B cell enriched
 peripheral blood flow cytometry and bone marrow aspirates to evaluate the kinetics and MOA of
 MEMP1972a are collected only 24 hr after allergen challenge due to visit and sample volume
 limitations. It is known that maximal B cell responses are expected ~7 days after allergen
 stimulation. Therefore, the purpose of this research study will be to characterize the time
 course of B cell activation after allergen challenge, and more specifically measure the M1
 prime related biomarkers.
Inclusion Criteria:

 -  Male and female volunteers 18 through 65 years of age.

 -  Females must not be actively seeking pregnancy, must be using adequate and effective
 contraception

 -  General good health

 -  Mild to moderate, stable, allergic asthma

 -  History of episodic wheeze and shortness of breath; FEV1 at baseline at least 70% of
 the predicted value

 -  Able to understand and give written informed consent and has signed a written informed
 consent form approved by the investigator's REB

 -  Positive methacholine challenge

 -  Positive skin-prick test to common aeroallergens (including cat, dust mite, grass,
 pollen)

 -  Positive allergen-induced airway bronchoconstriction (a fall in FEV1 of at least 20%
 from baseline)

 Exclusion Criteria:

 -  A worsening of asthma or a respiratory tract infection within 6 weeks preceding study
 entry

 -  History of clinically significant hypotensive episodes or symptoms of fainting,
 dizziness, or lightheadedness

 -  History or symptoms of clinically significant autoimmune disease

 -  History of clinically significant hematologic abnormality, including coagulopathy

 -  Be pregnant or lactating

 -  Use of corticosteroids, immunosuppressives, anticoagulants (warfarin or heparin)
 within 28 days prior to randomization into the study

 -  Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours of dosing or
 aspirin with 7 days of dosing

 -  Have chronic use of any other medication for treatment of allergic lung disease other
 than short- and intermediate-acting ß2-agonists or ipratropium bromide

 -  Use of caffeine-containing products or medications for 12 hours or alcohol or over the
 counter drugs including aspirin, cold and allergy medications for 48 hours or inhaled
 bronchodilators for 8 hours prior to methacholine and allergen challenges

 -  Use of tobacco products of any kind currently or within the previous 12 months, or
 smoking history > 10 pack years.

 -  Lung disease other than mild to moderate allergic asthma

 -  Unwillingness or inability to comply with the study protocol for any other reason.